MENU
About
Overview
Leadership Team
Board of Directors
Investors
Contact Us
Our science
Pipeline
Partnerships
News
Press Releases
Events & Presentations
News Coverage
Careers
Culture & Values
Competitive Benefits
Current Opportunities
CONTACT US
858.285.4000
info@locanabio.com
share
HOME
NEWS
WORTHY
NEWS
WORTHY
Press Releases
SEPTEMBER 14, 2020
Treatment with RNA-Targeting Gene Therapy Reverses Molecular and Functional Features of Myotonic Dystrophy Type 1 in Mice
SAN DIEGO, Sept. 14, 2020 /PRNewswire/ -- Locanabio, Inc., a leader in RNA-targeted gene therapy, today announced that results from a preclinical study of the company's therapeutic systems for the...
READ MORE
April 1, 2020
Locana Expands Leadership Team With Appointment of Micah Mackison, as Chief Business Officer
SAN DIEGO, Apr. 1, 2020 – Locana, Inc., a leading RNA-targeting gene therapy company, today announced the appointment of Micah Mackison, as Chief Business Officer. Bringing more than 20 years of...
READ MORE
MORE
December 10, 2019
Locana Expands Leadership Team With Appointment of former Casebia CEO, James Burns, Ph.D., as Chief Executive Officer
SAN DIEGO, Dec. 10, 2019 – Locana, Inc., a leading RNA-targeting gene therapy company, today announced the appointment of James Burns, Ph.D., as chief executive officer, as a key step in expanding...
READ MORE
September 23, 2019
Biocom Announces Fourth Annual Catalyst Award Winners
Life science trailblazers under the age of 40 recognized across California SAN DIEGO--(BUSINESS WIRE)--Biocom, the association representing the California life science industry, today announced...
READ MORE
September 4, 2019
Locana Appoints Kathie Bishop, Ph.D., as Chief Scientific Officer
SAN DIEGO, Sept. 4, 2019 /PRNewswire/ – Locana, a leading RNA-targeting gene therapy company, today announced the appointment of Kathie M. Bishop, Ph.D. as chief scientific officer. Dr. Bishop is a...
READ MORE
June 12, 2019
MDA Awards Venture Philanthropy Grant to Locana to Develop Novel Treatment for Muscular Dystrophy
NEW YORK and SAN DIEGO – June 12, 2019 – The Muscular Dystrophy Association (MDA) and Locana, a leading RNA-targeting gene therapy company, today announced the award of an MDA Venture...
READ MORE
May 22, 2019
Locana Raises $55 Million Series A Financing to Advance Portfolio of RNA-targeting Gene Therapies
Jeffrey M. Ostrove, Ph.D., named chief executive officer Proprietary technology based on pioneering work from the lab of Eugene (Gene) Yeo, Ph.D. of UC San Diego SAN DIEGO – May 22, 2019 –...
READ MORE
EVENTS & PRESENTATIONS
OCTOBER 8, 2020
Locanabio to Participate in Multiple Upcoming Industry Conferences in Q4 2020
READ MORE
MAY 27, 2020
Locana Participates in the 25th Annual Meeting of the RNA Society to Share Research Regarding RNA-targeting Gene Therapy for Human Genetic Diseases.
READ MORE
MAY 13, 2020
Locana Presents Poster at ASGCT 2020: AAV9 Mediated Delivery of RNA Targeting CRISPR Corrects Molecular and Functional Phenotypes in Myotonic Dystrophy Type 1 Mouse Model
READ MORE
News Coverage
October 8 2020,
BIOTECH 2050
Ep. 33 – James Burns PhD and Kathie Bishop PhD, CEO and CSO, Locanabio
READ MORE
September 23 2020,
BIOSPACE
Locanabio’s RNA-Targeting Gene Therapy May Offer Durable Response for DM1 Patients
READ MORE
August 3 2020,
CELL & GENE
The RNA-Targeting Era in Genetic Medicine
READ MORE
July 22 2020,
Biospace
Locanabio’s Combo RNA Modification Platform Targets Multiple RNA Dysfunctions with One Injection
READ MORE
July/August 2020,
DDNews
Q&A: Branching out with RNA-targeting Cas systems
READ MORE
July 11, 2020
Locanabio has been presented an excellence in RNA research RNA SOCIETY Poster Award at RNA 2020 On-line – the 25th Annual Meeting of the RNA SOCIETY
READ MORE
September 23, 2019
Biocom Announces Fourth Annual Catalyst Award Winners
READ MORE
